Patents by Inventor Rajendra K. Pandey
Rajendra K. Pandey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230365970Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).Type: ApplicationFiled: July 28, 2023Publication date: November 16, 2023Applicant: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
-
Publication number: 20230332153Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).Type: ApplicationFiled: November 29, 2022Publication date: October 19, 2023Applicant: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
-
Publication number: 20230159929Abstract: Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.Type: ApplicationFiled: September 7, 2022Publication date: May 25, 2023Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
-
Patent number: 11549110Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).Type: GrantFiled: February 15, 2022Date of Patent: January 10, 2023Assignee: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
-
Publication number: 20220380770Abstract: The present invention is in the field of pharmaceutical compounds and preparations and method of their use in the treatment of disease. Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions containing the same, and uses thereof for treating or preventing coronavirus infections. In particular, the present invention is in the field of siNA molecules effective against a broad spectrum of coronaviruses, and especially the ?-coronaviruses, including SARS-CoV-2, the causative agent of COVID-19.Type: ApplicationFiled: April 9, 2021Publication date: December 1, 2022Applicant: ALIGOS THERAPEUTICS, INC.Inventors: Leonid BEIGELMAN, Antitsa STOYCHEVA, Aneerban BHATTACHARYA, David Bernard SMITH, Rajendra K. PANDEY, Saul Martinez MONTERO, Vivek Kumar RAJWANSHI, Jin HONG
-
Publication number: 20220364096Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).Type: ApplicationFiled: March 5, 2021Publication date: November 17, 2022Applicant: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
-
Patent number: 11466274Abstract: The disclosure includes antisense oligonucleotides, including gapmer antisense oligonucleotides, along with methods of making and use, e.g., against HBV.Type: GrantFiled: May 29, 2020Date of Patent: October 11, 2022Assignee: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Rajendra K. Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Jin Hong
-
Publication number: 20220177888Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).Type: ApplicationFiled: February 15, 2022Publication date: June 9, 2022Applicant: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
-
Publication number: 20210317457Abstract: The present disclosure relates to the field of pharmaceutical compounds and preparations and method of their use in the treatment of disease. Described are antisense oligonucleotide (ASO) molecules, compositions containing the same, and uses thereof for treating or preventing coronavirus infections. In particular, the present disclosure provides specific ASOs that are effective against a broad spectrum of coronaviruses, and especially the ?-coronaviruses, including SARS-CoV-2, the causative agent of COVID-19.Type: ApplicationFiled: April 9, 2021Publication date: October 14, 2021Applicant: ALIGOS THERAPEUTICS, INC.Inventors: Leonid BEIGELMAN, Antitsa STOYCHEVA, Aneerban BHATTACHARYA, David Bernard SMITH, Rajendra K. PANDEY, Saul Martinez MONTERO, Vivek Kumar RAJWANSHI, Jin HONG
-
Publication number: 20210040483Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? position(s) along with methods of making and use, e.g., against HBV are disclosed.Type: ApplicationFiled: October 5, 2020Publication date: February 11, 2021Applicant: Janssen Biopharma, Inc.Inventors: Sergei GRYAZNOV, Leonid BEIGELMAN, Antitsa Dimitrova STOYCHEVA, Saul MARTINEZ MONTERO, Jin HONG, Rajendra K. PANDEY, Vivek Kumar RAJWANSHI, Lakshmipathi PANDARINATHAN, Yi JIN, Bharat BARAL
-
Publication number: 20200385735Abstract: The disclosure includes antisense oligonucleotides, including gapmer antisense oligonucleotides, along with methods of making and use, e.g., against HBV.Type: ApplicationFiled: May 29, 2020Publication date: December 10, 2020Applicant: Aligos Therapeutics, Inc.Inventors: Leonid Beigelman, Rajendra K. Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Jin Hong
-
Patent number: 10793859Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? positions(s) along with methods of making and use, e.g., against HBV are disclosed.Type: GrantFiled: September 14, 2017Date of Patent: October 6, 2020Assignee: Janssen BioPharma, Inc.Inventors: Sergei Gryaznov, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Saul Martinez Montero, Jin Hong, Rajendra K. Pandey, Vivek Kumar Rajwanshi, Lakshmipathi Pandarinathan, Yi Jin, Bharat Baral
-
Publication number: 20200270611Abstract: Modified oligonucleotides comprising a GalNAc moiety of the present disclosure along with methods of making and use, e.g., against HBV are disclosed.Type: ApplicationFiled: September 14, 2018Publication date: August 27, 2020Inventors: Sergei GRYAZNOV, Jin HONG, Rajendra K. PANDEY, Vivek Kumar RAJWANSHI
-
Publication number: 20190048344Abstract: The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.Type: ApplicationFiled: August 16, 2018Publication date: February 14, 2019Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Takeshi Yamada, David Butler, Jayaprakash K. Nair, Muthusamy Jayaraman, Shigeo Matsuda, Rajendra K. Pandey, Chang Geng Peng
-
Publication number: 20150203847Abstract: The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.Type: ApplicationFiled: December 31, 2014Publication date: July 23, 2015Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, Takeshi YAMADA, David BUTLER, Narayanannair K. JAYAPRAKASH, Muthusamy JAYARAMAN, Shigeo MATSUDA, Rajendra K. PANDEY, Chang Geng PENG
-
Patent number: 8962580Abstract: The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.Type: GrantFiled: September 23, 2009Date of Patent: February 24, 2015Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Takeshi Yamada, David Butler, Narayanannair K. Jayaprakash, Muthusamy Jayaraman, Shigeo Matsuda, Rajendra K. Pandey, Chang Geng Peng
-
Patent number: 8946175Abstract: The invention provides immunostimulatory oligonucleotides having at least one CpG dinucleotide and a secondary structure at the 5?- or 3?-end. These oligonucleotides have either reduced or improved immunostimulatory properties. The invention establishes that 5?-terminal secondary structures affect immunostimulatory activity significantly more than those at the 3?-end. The invention also provides methods for increasing or decreasing the immunostimulatory activity of a CpG-containing nucleic acid.Type: GrantFiled: August 16, 2011Date of Patent: February 3, 2015Assignee: Idera Pharmaceuticals, Inc.Inventors: Ekambar R. Kandimalla, Lakshmi Bhagat, Rajendra K. Pandey, Dong Yu, Sudhir Agrawal
-
Patent number: 8431693Abstract: The present invention relates to processes and reagents for oligonucleotide synthesis and purification. One aspect of the present invention relates to compounds useful for activating phosphoramidites in oligonucleotide synthesis. Another aspect of the present invention relates to a method of preparing oligonucleotides via the phosphoramidite method using an activator of the invention. Another aspect of the present invention relates to sulfur-transfer agents. In a preferred embodiment, the sulfur-transfer agent is a 3-amino-1,2,4-dithiazolidine-5-one. Another aspect of the present invention relates to a method of preparing a phosphorothioate by treating a phosphite with a sulfur-transfer reagent of the invention. In a preferred embodiment, the sulfur-transfer agent is a 3-amino-1,2,4-dithiazolidine-5-one. Another aspect of the present invention relates to compounds that scavenge acrylonitrile produced during the deprotection of phosphate groups bearing ethylnitrile protecting groups.Type: GrantFiled: February 28, 2011Date of Patent: April 30, 2013Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Michael F. Jung, Kallanthottathil G. Rajeev, Rajendra K. Pandey, Gang Wang
-
Publication number: 20120035115Abstract: The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.Type: ApplicationFiled: September 23, 2009Publication date: February 9, 2012Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Takeshi Yamada, David Butler, K. Narayanannair Jayaprakash, Muthusamy Jayraman, Shigeo Matsuda, Rajendra K. Pandey, Chang Geng Peng
-
Patent number: 8063198Abstract: The present invention relates to processes and reagents for oligonucleotide synthesis and purification. One aspect of the present invention relates to compounds useful for activating phosphoramidites in oligonucleotide synthesis. Another aspect of the present invention relates to a method of preparing oligonucleotides via the phosphoramidite method using an activator of the invention. Another aspect of the present invention relates to sulfur-transfer agents. In a preferred embodiment, the sulfur-transfer agent is a 3-amino-1,2,4-dithiazolidine-5-one. Another aspect of the present invention relates to a method of preparing a phosphorothioate by treating a phosphite with a sulfur-transfer reagent of the invention. In a preferred embodiment, the sulfur-transfer agent is a 3-amino-1,2,4-dithiazolidine-5-one. Another aspect of the present invention relates to compounds that scavenge acrylonitrile produced during the deprotection of phosphate groups bearing ethylnitrile protecting groups.Type: GrantFiled: March 18, 2008Date of Patent: November 22, 2011Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Michael E. Jung, Kallanthottathil G. Rajeev, Rajendra K. Pandey, Gang Wang